In this video from ASH, Prof. Wojciech Jurczak, consultant hematologist and Head of Department at the Maria Skłodowska-Curie National Research Institute of Oncology, shares key results from the randomized BRUIN CLL-313 study comparing pirtobrutinib with bendamustine–rituximab in patients with previously untreated CLL.
He highlights the significant and clinically meaningful improvement in progression-free survival observed with pirtobrutinib, discusses emerging overall survival trends, and reflects on how these findings may influence future first-line treatment strategies. The conversation also explores safety outcomes and practical considerations when choosing between time-limited and continuous therapies across different patient populations.
